Pharmaceutical & Life Sciences News

Chinese Money Floods U.S. Biotech as Beijing Chases New Cures

April 18, 2018, 9:26 PM

Chinese investors are pumping money into U.S. drug startups as Beijing seeks to become a global leader in new medicines, adding to a flood of cash flowing to groundbreaking health firms.

Venture-capital funds based in China poured $1.4 billion into private U.S. biotechnology firms in the three months ending March 31, accounting for about 40 percent of the $3.7 billion that the companies raised in the period overall, according to data provider PitchBook. At the same time a year earlier, Chinese funds invested $125.5 million, only about 7 percent of the total.

Policy makers want to encourage more innovation in...

To read the full article log in. To learn more about a subscription click here.